Exposure-response relationship of certolizumab pegol induction and maintenance therapy in patients with Crohn's disease.

about

Editorial: early post-induction anti-TNF drug monitoring can predict long-term therapeutic outcomes in inflammatory bowel disease.

P2860

Q48288875-BEAF539A-25ED-4C84-B0EC-7A2AAEE421EF

P2860

Exposure-response relationship of certolizumab pegol induction and maintenance therapy in patients with Crohn's disease.

Item

http://www.wikidata.org/entity/Q46756144

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Exposure-response relationship ...... patients with Crohn's disease.

@en

Exposure-response relationship ...... patients with Crohn's disease.

@nl

type

Item

label

Exposure-response relationship ...... patients with Crohn's disease.

@en

Exposure-response relationship ...... patients with Crohn's disease.

@nl

prefLabel

Exposure-response relationship ...... patients with Crohn's disease.

@en

Exposure-response relationship ...... patients with Crohn's disease.

@nl

P1476

Exposure-response relationship ...... patients with Crohn's disease.

@en

P2093

G Kosutic

http://www.w3.org/2001/XMLSchema#string

J Coarse

http://www.w3.org/2001/XMLSchema#string

M Yassine

http://www.w3.org/2001/XMLSchema#string

S Vermeire

http://www.w3.org/2001/XMLSchema#string

P2860

Certolizumab pegol for the treatment of Crohn's disease

A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease

Association between plasma concentrations of certolizumab pegol and endoscopic outcomes of patients with Crohn's disease.

Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease.

Pharmacokinetics and Exposure-response Relationship of Golimumab in Patients with Moderately-to-Severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT Induction and Maintenance Studies.

Systematic review: antibodies and anti-TNF-α levels in inflammatory bowel disease.

Therapeutic drug monitoring of tumor necrosis factor antagonists in inflammatory bowel disease.

Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis.

Antibodies to infliximab and risk of infusion reactions in patients with inflammatory bowel disease: a systematic review and meta-analysis.

Therapeutic drug monitoring in inflammatory bowel disease: current state and future perspectives.

P304

229-237

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/APT.14421

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Niels Vande Casteele

William Jeffery Sandborn

Brian G. Feagan

P577

2017-11-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29159893

http://www.w3.org/2001/XMLSchema#string

P932

5765392

http://www.w3.org/2001/XMLSchema#string

Exposure-response relationship of certolizumab pegol induction and maintenance therapy in patients with Crohn's disease.

about

P2860

P2860

Exposure-response relationship of certolizumab pegol induction and maintenance therapy in patients with Crohn's disease.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932